Evomedis
EVOMEDIS is a research and development stage life science company based in Graz, Austria, focused on developing innovative wound healing solutions. Their mission is to shift the paradigm from wound care to wound healing, addressing high unmet needs in chronic wound and burn treatment. They develop next-generation wound healing solutions such as EVOSens, a non-invasive wound monitoring sensor, EVOCellic, a shelf-ready tissue-engineered skin substitute, and EVOSource, a platform supporting wound care R&D projects. The company collaborates with global partners and research institutions, and is involved in advancing regenerative medicine and wound healing technologies.
Industries
Nr. of Employees
small (1-50)
Evomedis
ZWT II / 4.OG, Stiftingtalstraße 14, 8010 Graz, Austria
Products
Non-invasive pH-sensing wound dressing
A sterile wound dressing with an integrated colorimetric sensor that provides a localized visual readout of wound pH in real time to guide dressing changes and therapy decisions without fluid sampling.
Shelf-ready allogeneic keratinocyte skin substitute
A cell-based, tissue-engineered skin substitute composed of preserved allogeneic keratinocytes formulated to release growth factors on application, intended to accelerate wound closure in deep dermal burns and chronic wounds.
Non-invasive pH-sensing wound dressing
A sterile wound dressing with an integrated colorimetric sensor that provides a localized visual readout of wound pH in real time to guide dressing changes and therapy decisions without fluid sampling.
Shelf-ready allogeneic keratinocyte skin substitute
A cell-based, tissue-engineered skin substitute composed of preserved allogeneic keratinocytes formulated to release growth factors on application, intended to accelerate wound closure in deep dermal burns and chronic wounds.
Services
Project-based R&D services covering preclinical skin models, ex vivo efficacy and mode-of-action studies, animal wound models, clinical trial organization and clinical consulting through a partner network.
Project-based R&D services covering preclinical skin models, ex vivo efficacy and mode-of-action studies, animal wound models, clinical trial organization and clinical consulting through a partner network.
Expertise Areas
- Wound healing therapeutics
- Tissue engineering of skin substitutes
- Cell preservation and lyophilization
- Preclinical wound models (in vitro, ex vivo, animal)
Key Technologies
- Colorimetric pH sensing integrated into dressings
- Lyophilization (freeze-drying) of therapeutic cells
- Allogeneic keratinocyte-based tissue-engineered skin substitutes
- 3D in vitro skin models
News & Updates
EVOMEDIS pledges €1.5 million over two years to develop EVOCellic, a ready-to-use cell-based wound healing solution for burns and chronic wounds, in collaboration with local research institutions.
EVOMEDIS received orphan drug designation from the European Medicines Agency for EVOCellic, a cell therapy for severe burns.
Research on wound healing by controlling moisture content, published in Biomedicines.
Development of a 3D in vitro burn wound model for monitoring regeneration, published in Biomedicines.
EVOCellic received orphan drug designation from the European Medicines Agency for burn treatment.
EVOMEDIS pledges €1.5 million over two years to develop EVOCellic, a ready-to-use cell-based wound healing solution for burns and chronic wounds, in collaboration with local research institutions.
EVOMEDIS received orphan drug designation from the European Medicines Agency for EVOCellic, a cell therapy for severe burns.
Research on wound healing by controlling moisture content, published in Biomedicines.
Development of a 3D in vitro burn wound model for monitoring regeneration, published in Biomedicines.
EVOCellic received orphan drug designation from the European Medicines Agency for burn treatment.